Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement
Authors:
- Erman AytaçEAErman Aytaç
- Leyla ÖzErLOLeyla ÖzEr
- Bilgi BacaBBBilgi Baca
- Emre BalıkEBEmre Balık
- Yersu KapranYKYersu Kapran
- Orhun Cığ TaşkInOTOrhun Cığ TaşkIn
- BaşaK Oyan UluçBUBaşaK Oyan Uluç
- Mehmet Ufuk AbacıoğluMAMehmet Ufuk Abacıoğlu
- Murat GönEnçMGMurat GönEnç
- Yasemin BölÜkBaşıYBYasemin BölÜkBaşı
- Barbaros E. ÇiLBCBarbaros E. ÇiL
- BülEnt BaranBBBülEnt Baran
Open Access
- 1 August 2022
- journal article
- review article
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 33 (8) , 627-663
Abstract
Colorectal cancer is the third most common cancer in Turkey. The current guidelines do not provide sufficient information to cover all aspects of the management of rectal cancer. Although treatment has been standardized in terms of the basic principles of neoadjuvant, surgical, and adjuvant therapy, uncertainties in the management of rectal cancer may lead to significant differences in clinical practice. In order to clarify these uncertainties, a consensus program was constructed with the participation of the physicians from the Acıbadem Mehmet Ali Aydınlar and Koç Universities. This program included the physicians from the departments of general surgery, gastroenterology, pathology, radiology, nuclear medicine, medical oncology, radiation oncology, and medical genetics. The gray zones in the management of rectal cancer were determined by reviewing the evidence-based data and current guidelines before the meeting. Topics to be discussed consisted of diagnosis, staging, surgical treatment for the primary disease, use of neoadjuvant and adjuvant treatment, management of recurrent disease, screening, follow-up, and genetic counseling. All those topics were discussed under supervision of a presenter and a chair with active participation of related physicians. The consensus text was structured by centralizing the decisions based on the existing data. Cite this article as: Aytaç E, Özer L, Baca B, et al. Optimizing the personalized care for the management of rectal cancer: A consensus statement. Turk J Gastroenterol. 2022;33(8):627-663.Keywords
This publication has 102 references indexed in Scilit:
- Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal CancerJNCI: Journal of the National Cancer Institute, 2009
- Capecitabine Initially Concomitant to Radiotherapy Then Perioperatively Administered in Locally Advanced Rectal CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Surrogate end points for overall survival and local control in neoadjuvant rectal cancer trials: statistical evaluation based on the FFCD 9203 trialAnnals of Oncology, 2009
- Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trialThe Lancet, 2009
- Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trialThe Lancet, 2009
- Deficient mismatch repair system in patients with sporadic advanced colorectal cancerBritish Journal of Cancer, 2009
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal CancerNew England Journal of Medicine, 2008
- Defunctioning Stoma Reduces Symptomatic Anastomotic Leakage After Low Anterior Resection of the Rectum for CancerAnnals of Surgery, 2007
- Safe liver resection following chemotherapy for colorectal metastases is a matter of timingBritish Journal of Cancer, 2007
- Complete Response of Colorectal Liver Metastases After Chemotherapy: Does It Mean Cure?Journal of Clinical Oncology, 2006